| EMA number | EMEA/H/C/004826 |
| ATC code | L01XE02 |
| Authorisation | 27 September 2018 |
| Withdrawn | 27 September 2024 |
| Revision | 7 |
Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with activating mutations of EGFR TK.